Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
Ajay K. Nooka, Keith Stockerl‐Goldstein, Hang Quach, Adam Forbes, María‐Victoria Mateos, Amit Khot, Alan Tan, Rafat Abonour, Bikramjit Chopra, Rachel Rogers, Geraldine Ferron‐Brady, Jacqueline Davidge, Steve Frey, Anne Yeakey, Mala K. Talekar, Katarina Luptakova, Ira Gupta, Rakesh Popat (2020). DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).. , 38(15_suppl), DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.8502.
Article278 days agoDREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)
Rakesh Popat, Ajay K. Nooka, Keith Stockerl‐Goldstein, Rafat Abonour, Ryan Ramaekers, Amit Khot, Adam Forbes, Cindy Lee, Bradley Augustson, Andrew Spencer, María‐Victoria Mateos, Bikramjit Chopra, Rachel Rogers, Deborah A. Smith, Jacqueline Davidge, Rocío Montes de, Geraldine Ferron‐Brady, Anne Yeakey, Mala K. Talekar, Brandon E. Kremer, Ira Gupta, Hang Quach (2020). DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM). , 136(Supplement 1), DOI: https://doi.org/10.1182/blood-2020-139332.
Article278 days agoMM-691: Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM)
Meletios A Dimopoulos, Peter W. Voorhees, F. Hellem Schjesvold, Yaël C. Cohen, Vânia Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark‐David Levin, Meral Beksac, Keith Stockerl‐Goldstein, Albert Oriol, Gábor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špıčka, Anne K. Mylin, Sara Galimberti, Katarina Uttervall, Bartosz Puła, Eva Medvedova, Andrew J. Cowan, Philippe Moreau, María‐Victoria Mateos, Hartmut Goldschmidt, Tahamtan Ahmadi, Linlin Sha, Annelore Cortoos, Eva G. Katz, Els Rousseau, Liang Li, Robyn M. Dennis, Robin Carson, S. Vincent Rajkumar (2025). MM-691: Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM). , 25, DOI: https://doi.org/10.1016/s2152-2650(25)02630-8.
Article23 days agoPOSTER: MM-691 Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM)
Meletios A Dimopoulos, Peter W. Voorhees, F. Hellem Schjesvold, Yaël C. Cohen, Vânia Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark‐David Levin, Meral Beksac, Keith Stockerl‐Goldstein, Albert Oriol, Gábor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špıčka, Anne K. Mylin, Sara Galimberti, Katarina Uttervall, Bartosz Puła, Eva Medvedova, Andrew J. Cowan, Philippe Moreau, María‐Victoria Mateos, Hartmut Goldschmidt, Tahamtan Ahmadi, Linlin Sha, Annelore Cortoos, Eva G. Katz, Els Rousseau, Liang Li, Robyn M. Dennis, Robin Carson, S. Vincent Rajkumar (2025). POSTER: MM-691 Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM). , 25, DOI: https://doi.org/10.1016/s2152-2650(25)01280-7.
Article23 days agoDaratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age
Peter M. Voorhees, Meletios A Dimopoulos, Yaël C. Cohen, Fredrik Schjesvold, Vânia Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark‐David Levin, Meral Beksaç, Keith Stockerl‐Goldstein, Hila Magen, Albert Oriol, Gábor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špıčka, Anne K. Mylin, Simon Hallam, Sara Galimberti, Katarina Uttervall, Bartosz Puła, Abdullah Khan, Eva Medvedova, J Christine Ye, Andrew J. Cowan, Philippe Moreau, María‐Victoria Mateos, Hartmut Goldschmidt, Diego Vieyra, Abid Raval, Linlin Sha, Liang Li, Els Rousseau, Robyn M. Dennis, Robin Carson, S. Vincent Rajkumar (2025). Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-372.
Article23 days ago